WHWK: aadibio.com Company Value to Net Income

Aadi Bioscience - graphic logo of issuer WHWK

The price chart on the GURU.Markets platform helps assess the management efficiency of the precision oncology expert team, where the indicator stands at -2.30. The Aadi Bioscience Inc (WHWK) business relies on the development of albumin-based drugs for targeted therapy delivery to tumors. Aadi Bioscience Inc (WHWK) generates revenue from stable demand from oncology centers, focusing on the treatment of rare sarcomas and expanding its therapeutic spectrum.

Price to Earnings Ratio: Aadi Bio (WHWK) for 03/20/2025 - 11/12/2026

Comprehensive metric breakdowns and analytics for Aadi Bioscience, Inc. (WHWK)

- share price and expert price forecast:
Price Performance Chart Aadi Bio|WHWK - Consensus Target
- market capitalization information:
Market Value Aadi Bioscience Inc|WHWK - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Aadi Bioscience|WHWK - Company Net Assets|Market Capitalization to Book Value Ratio aadibio.com|WHWK - Aggregate Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Aadi Bioscience Inc|WHWK - Long-Term Debt to Capital|Current Liabilities to Capital Aadi Bio|WHWK - Company Aggregate Debts|Debts to Book Capitalization Aadi Bioscience Inc|WHWK - Company Long-Term Debts|Company Short-Term Debts Aadi Bioscience|Immediate Liquidity Ratio aadibio.com
- company profitability and valuation multiples indicators:
WHWK - Net Profit|Company Profit Forecast Aadi Bioscience Inc|WHWK - Price to Earnings Ratio|Future Price to Earnings Multiple Aadi Bio|WHWK - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience Inc|WHWK - Operating profit EBITDA|Net earnings per share for the last four quarters Aadi Bioscience|WHWK - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months aadibio.com|WHWK - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Aadi Bioscience Inc
Summary company analysis:WHWK, aadibio.com
Flagship merchandise of Aadi Bioscience

The P/E ratio determines the cost of one dollar of net profit, reflecting the proportion between market capitalization and the actual financial result of the business. Analyzing the current P/E multiple valuation allows for an assessment of overpayment risks, which is critical for Aadi Bioscience Inc. (WHWK), whose future excess profits depend on the scalability of low-cost targeted therapy production following regulatory approval.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Erasca Inc - Company Value to Net Income|DCTH (Delcath) - P/E Multiple|Market Cap to Earnings Y-mAbs Corp YMAB|P/E Multiple AURA|P/E Multiple candeltx.com (CADL)|P/E Multiple ARAY (Accuray)|P/E Multiple SELLAS Life Sciences Group, Inc. SLS|Actuate Therapeutics, Inc - P/E Multiple|CTOR (Citius Oncology Inc) - Price to Earnings Multiple|HURA: P/E Multiple|TARA - Business Payback Period|Price to Earnings Ratio FATE|TCRX: Company Value to Net Income|P/E Multiple CSBR|Price to Earnings Ratio XBIT (xbiotech.com)|P/E Multiple CVM (CEL-SCI)|Business Payback Period ostherapies.com (OSTX)|RADX - Price to Earnings Ratio|Market Cap to Earnings Artiva Biotherapeutics, Inc.|adlainortye.com (ANL) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics) - P/E Multiple|Price to Earnings Ratio Xilio (XLO)|P/E Multiple RENB|Business Payback Period muraloncology.com|P/E Multiple KAPA (Kairos Pharma)|OnKure Therapeutics, Inc. (OKUR) - Market Cap to Earnings|GDTC - Price to Earnings Ratio|CRIS (Curis, Inc.) - Price to Earnings Multiple|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune Inc|ADVB (Advanced Biomed Inc.) - P/E Multiple|Market Cap to Earnings Genprex Inc GNPX|Price to Earnings Ratio CLDI (Calidi Biotherapeutics)|SBFM (sunshinebiopharma.com) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences, Inc.)|Business Payback Period Salarius Pharmaceuticals Inc (SLRX)|PPBT - Price to Earnings Ratio|AONC (American Oncology Network) - Price to Earnings Multiple|BGNE: P/E Multiple|Price to Earnings Ratio checkpointtx.com|Price to Earnings Ratio ELEV|Price to Earnings Ratio iCAD Corp (ICAD)|P/E Multiple IKNA|NTBL (Notable Labs Corp) - Company Value to Net Income|Viracta Therapeutics, Inc. - Price to Earnings Ratio|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|AAPGV - P/E Multiple